MedTrace Logo

A Trial of Firesorb in Patients With Coronary Artery Disease: FUTURE-II

NCT02890160 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 430

Last updated 2023-10-25

No results posted yet for this study

Summary

The FUTURE-II study is a confirmative clinical trial for Sirolimus Target Eluting Bioresorbable Vascular Scaffold (Firesorb) after the feasibility and safety of the device has been preliminary confirmed in a small-scale First-in-Man clinical trial.

Conditions

Interventions

DEVICE

Firesorb

Sirolimus Target Eluting Bioresorbable Vascular Scaffold

DEVICE

XIENCE

Everolimus Eluting Coronary Stent System

Sponsors & Collaborators

  • Shanghai MicroPort Medical (Group) Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Runlin Gao, MD · Fu Wai Hospital & National Center for Cardiovascular Diseases in China

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-08-24
Primary Completion
2020-10-31
Completion
2024-10-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02890160 on ClinicalTrials.gov